Food Safety
SGLT1 inhibition causes gastrointestinal side effects
📅 Last reviewed: 2026-08-11 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
The honest counterweight to claim-sglt1-inhibition-decreases-postprandial-glucose. Blocking intestinal SGLT1 works by leaving glucose unabsorbed in the gut lumen, and that unabsorbed sugar is osmotically active and fermentable, so the mechanism of benefit is also the mechanism of the side effect — though the dose split in s36225203 (400 mg RR 1.67 significant vs 200 mg RR 1.
The evidence (3)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Zhou F, Du N, Zhou L, Wang C, Ren H, Sun Q 2022 · Front Endocrinol (Lausanne). 2022 Sep 26;13:968478 | meta-analysis | supports | moderate | Meta-analysis of 9 phase II/III RCTs, 15,519 patients (3,203 T1D; 12,316 T2D) of sotagliflozin vs placebo. Pooled DIARRHOEA across all doses: RR 1.44, 95% CI 1.28-1.62, p<0.001, I2=0 (Table 1: 'Diarrhoea 9 1.44 1.28-1.62'). By population: T1D 'RR: 1.44, 95% Cl: 1.09-1.90, p = 0.01'; T2D 'RR: 1.44, 95% Cl: 1.26-1.64, p < 0.001'. Dose-split: 400 mg 'could also increase the risk of diarrhea (RR: 1.70, 95% Cl: 1.19-2.42, p < 0.01)', 200 mg NOT significant ('Diarrhoea 5 1.25 0.82-1.90 0.29 0 Fixed'). Authors attribute the effect to the claim's subject: 'The increased incidence of diarrhea and volume depletion ( 12 ) may be related to the inhibition of SGLT1, one of the binding sites of sotagliflozin.' Overall verdict framed as tolerable: 'This meta-analysis showed that the adverse events of sotagliflozin were tolerable to patients with DM'. CORRECTION (2026-08-19 re-read): the figure RR 1.25 (1.07-1.45) previously carried here is this paper's T2D VOLUME DEPLETION result (Figure 6D), not diarrhoea — it was read off the wrong half of a 'respectively' pair. Quality moderate, not high: all nine pooled RCTs are the single Lexicon/Sanofi sotagliflozin (LX4211) programme, no PROSPERO registration is stated, Begg's/Egger's testing was run only for genital mycotic infection, and the risk-of-bias paragraph credits 'Two investigators (A.A. and N.A.)' with adjudication by 'I.A.' — initials matching none of the six authors. |
| Avgerinos I, Karagiannis T, Kakotrichi P, Michailidis T, Liakos A, Matthews DR, Tsapas A, Bekiari E 2022 · Diabetes Obes Metab 2022 Jan;24(1):106-114 | meta-analysis | supports | high | Systematic review and meta-analysis of RCTs of sotagliflozin (dual SGLT1/SGLT2 inhibitor) in type 2 diabetes; 11 RCTs, 16 411 subjects; 1 primary efficacy outcome (HbA1c) plus 3 secondary efficacy and 15 SAFETY outcomes, searched to August 2021. Safety result: 'Treatment with sotagliflozin was safe regarding the incidence of serious adverse events, hypoglycaemia, and diabetic ketoacidosis. Nevertheless, it was associated with an increased incidence of diarrhoea, genital infections, and volume depletion events.' The diarrhoea signal here is DIRECTIONAL ONLY — no odds ratio, confidence interval or event count is reported in the abstract, which is all that could be read (paper paywalled, no local full text); the RR 1.25 (95% CI 1.07-1.45) cited in the claim body comes from the sibling meta-analysis s36225203, not from this source. Authors' own framing tempers the SGLT1-specific reading: 'Its overall safety profile is comparable with other sodium-glucose co-transporter-2 inhibitors.' |
| Dos Santos Borges R, de Oliveira Almeida G, Alves VFC, Nienkotter TF, Bertoli ED, Simoes E Silva AC 2024 · Journal of nephrology | meta-analysis | supports | moderate | Meta-analysis of 3 placebo-controlled RCTs / 11,648 patients with T2DM and CKD, mean follow-up 15.7 +/- 5.9 months (PROSPERO CRD42023449631): 'diarrhea (RR 1.42; 95% CI [1.24. 1.63]; p < 0.00001; I2 = 0%) ... were more common with Sotagliflozin', alongside genital mycotic infections (RR 2.73) and volume depletion (RR 1.31). The GI signal is precise and heterogeneity-free, but sotagliflozin is a DUAL SGLT1/2 inhibitor and the paper makes no SGLT1-specific attribution; the three trials are a subset of the same sponsor programme pooled by s36225203, so this is not an independent confirmation. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.